➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
AstraZeneca
McKinsey
Baxter

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PIFELTRO

« Back to Dashboard

All Clinical Trials for PIFELTRO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03886701 Doravirine, Rifapentine and Isoniazid Interaction Not yet recruiting Merck Sharp & Dohme Corp. Phase 1 2019-04-01 Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes that share the same metabolic pathway as antiretroviral drugs used for those living with HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral drug when co-administered with a common anti-tuberculosis regimen of drugs.
NCT03886701 Doravirine, Rifapentine and Isoniazid Interaction Not yet recruiting Walter K. Kraft Phase 1 2019-04-01 Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes that share the same metabolic pathway as antiretroviral drugs used for those living with HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral drug when co-administered with a common anti-tuberculosis regimen of drugs.
NCT03894124 Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers Not yet recruiting Imperial College London Phase 1 2019-06-01 Study to assess the pharmacokinetics of plasma doravirine once daily over 72 hours following drug intake cessation at steady-state in healthy volunteers
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PIFELTRO

Condition Name

Condition Name for PIFELTRO
Intervention Trials
Human Immunodeficiency Virus 2
Rifamycins Causing Adverse Effects in Therapeutic Use 1
Latent Tuberculosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PIFELTRO
Intervention Trials
Immunologic Deficiency Syndromes 2
HIV Infections 2
Acquired Immunodeficiency Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PIFELTRO

Trials by Country

Trials by Country for PIFELTRO
Location Trials
United Kingdom 2
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PIFELTRO

Clinical Trial Phase

Clinical Trial Phase for PIFELTRO
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PIFELTRO
Clinical Trial Phase Trials
Not yet recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PIFELTRO

Sponsor Name

Sponsor Name for PIFELTRO
Sponsor Trials
Merck Sharp & Dohme Corp. 3
Chelsea and Westminster NHS Foundation Trust 2
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PIFELTRO
Sponsor Trials
Other 6
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
Harvard Business School
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.